Evidence map›Paper›PMID 41893201›Full record

ReviewJournal of functional biomaterials2026

Calcium Phosphate Bone Substitutes in the Prevention of Bisphosphonate-Related Osteonecrosis of the Jaw: A Review.

Siri Paulo, Ana Margarida Abrantes, Mafalda Laranjo, Carlos Miguel Marto, Anabela Paula, Pedro Trancoso, Filomena Botelho, Arménio Serra, Manuel Marques Ferreira

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of functional biomaterials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Siri PauloInstitute of Endodontics, Faculty of Medicine, University of Coimbra, 3000-548 Coimbra, Portugal.ORCID 0000-0002-3914-2423
Ana Margarida AbrantesArea of Environment, Genetics and Oncobiology (CIMAGO), Faculty of Medicine, Coimbra Institute for Clinical and Biomedical Research (iCBR), University of Coimbra, 3000-548 Coimbra, Portugal.ORCID 0000-0003-4185-7871
Mafalda LaranjoArea of Environment, Genetics and Oncobiology (CIMAGO), Faculty of Medicine, Coimbra Institute for Clinical and Biomedical Research (iCBR), University of Coimbra, 3000-548 Coimbra, Portugal.ORCID 0000-0003-0689-6007
Carlos Miguel MartoArea of Environment, Genetics and Oncobiology (CIMAGO), Faculty of Medicine, Coimbra Institute for Clinical and Biomedical Research (iCBR), University of Coimbra, 3000-548 Coimbra, Portugal.ORCID 0000-0001-9269-5417
Anabela PaulaArea of Environment, Genetics and Oncobiology (CIMAGO), Faculty of Medicine, Coimbra Institute for Clinical and Biomedical Research (iCBR), University of Coimbra, 3000-548 Coimbra, Portugal.ORCID 0000-0001-6154-4173
Pedro TrancosoEgas Moniz School of Health & Science, Department of Oral Surgery and Oral Medicine, Campus Universitário, Quinta da Granja, Monte de Caparica, 2829-511 Caparica, Portugal.
Filomena BotelhoArea of Environment, Genetics and Oncobiology (CIMAGO), Faculty of Medicine, Coimbra Institute for Clinical and Biomedical Research (iCBR), University of Coimbra, 3000-548 Coimbra, Portugal.ORCID 0000-0001-7202-1650
Arménio SerraDepartment of Chemical Engineering, Faculty of Sciences and Technology, University of Coimbra, 3030-790 Coimbra, Portugal.
Manuel Marques FerreiraInstitute of Endodontics, Faculty of Medicine, University of Coimbra, 3000-548 Coimbra, Portugal.ORCID 0000-0002-5968-6161

Funding

Fundação para a Ciência e a Tecnologia (FCT) supports the Center for Innovative Biomedicine and Biotechnology through the UIDB/04539/2020 (10.54499/UIDB/04539/2020), UIDP/04539/2020 (10.54499/UIDP/04539/2020) and the Associated Laboratory funding LA/P/005 UIDB/04539/2020Fundação para a Ciência e Tecnologia UIDP/04539/2020
6 · The paper itself

Abstract

Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is characterized by exposed necrotic bone that often progresses with increasing pain and impaired quality of life. Zoledronate, the most potent and widely used bisphosphonate, has been strongly associated with BRONJ development following invasive dental procedures. Given the rising incidence of BRONJ, understanding and implementing effective preventive strategies have become imperative. Biomaterials based on synthetic hydroxyapatite and beta-tricalcium phosphate have been investigated as potential preventive agents. Their therapeutic rationale is supported by two key principles: the well-documented chemical interaction of calcium phosphates with bisphosphonates when used as drug carriers, and the established clinical use of synthetic calcium phosphate biomaterials in dentistry for bone regeneration. This review examines the underlying mechanisms of this preventive therapeutic strategy and evaluates studies investigating synthetic calcium phosphate biomaterials for BRONJ prevention through zoledronate adsorption at jaw wound sites, thereby reducing soft tissue toxicity and promoting healing. The evidence supports the protective effect of these biomaterials as a scientifically grounded preventive approach for BRONJ.

Indexed as

bisphosphonatesbone substitutescalcium phosphateosteonecrosis of jawpreventionsynthetic biomaterials

Identifiers

PMID41893201
PMCPMC13028528

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.